Hualan shares: Subsidiary plans to increase capital by 20 million yuan to invest in Keystone Biological.

Hualan Group announced on November 13th that its wholly-owned subsidiary Lingqing Intelligence and Shenzhen Jingtai plan to jointly increase their investment in KemoBio Technology Co., Ltd. Lingqing Intelligence plans to use 20 million yuan to subscribe to the new registered capital of KemoBio, further acquiring a 9.53% equity stake based on fully diluted basis after the transaction. After the completion of the transaction, Lingqing Intelligence will obtain a seat on KemoBio's board of directors and have a priority purchase right on equal terms with other shareholders. KemoBio was established in 2021 and is a biotechnology company focused on antibody design using generative AI models incubated by Jingtai, a leading global AI drug R&D company.